eIF4G1-eIF1 Inhibitors for Selective Translation Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inhibiting translation initiation in mammalian cells are limited by the complexity of protein-protein interactions, particularly the eIF4G1-eIF1 interaction, which is challenging to target with small molecules, and existing approaches are labor-intensive, expensive, and impractical for elucidating the in-vivo significance of eukaryotic translation initiation factors.
Innovation Solution
Development of small molecule inhibitors, such as i14G1-10 and i14G1-12, that specifically target the eIF4G1-eIF1 binding site, disrupting their interaction and modulating translation initiation, while also affecting the eIF4G1-eIF4E complex formation, thereby regulating translation initiation and stress-response gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule inhibitors are developed to target eIF4G1-eIF1 binding site, then translation initiation can be selectively inhibited, but the complexity of protein-protein interactions makes targeting challenging
Solution Approach 1:
The patent applies local quality by designing small molecules that specifically target the eIF4G1-eIF1 binding interface rather than attempting to disrupt the entire eIF4F complex. The inhibitors are structurally tailored to fit the specific spatial and chemical characteristics of the eIF1 binding site on eIF4G1, enabling selective disruption of this particular protein-protein interaction while leaving other interactions intact.
Solution Approach 2:
The small molecule inhibitors act as intermediary substances that mediate between the researcher's intent to inhibit translation and the biological target eIF4G1-eIF1 complex. These molecules serve as a bridge that translates the abstract goal of translation inhibition into a concrete molecular mechanism by occupying the eIF1 binding site and preventing natural ligand binding.
2Measurement precision
If existing methods are used to elucidate in-vivo significance of eukaryotic translation initiation factors, then research can be conducted, but the approaches are labor-intensive and expensive
Solution Approach 1:
The patent replaces complex mechanical and biochemical research methods (such as genetic manipulation, prolonged siRNA treatments, and overexpression studies) with a simpler chemical approach using small molecule inhibitors. This substitution allows researchers to study translation initiation mechanisms in vivo without the labor-intensive procedures previously required, reducing both time and resource investment.
Solution Approach 2:
The invention changes the fundamental parameter of how translation initiation is studied by shifting from genetic manipulation approaches to pharmacological inhibition approaches. This parameter change enables more efficient in vivo studies by using reversible, titratable small molecule inhibitors instead of irreversible genetic modifications, allowing for more flexible and efficient experimental designs.
3Productivity
If eIF4G1 interaction with eIF1 is inhibited, then translation initiation is reduced, but the dynamic nature of this interaction makes its regulatory role unknown
Solution Approach 1:
The patent applies preliminary action by using small molecule inhibitors to pre-occupy the eIF1 binding site on eIF4G1 before the natural eIF1 protein can bind. This preliminary chemical binding prevents the formation of the eIF4G1-eIF1 complex, allowing researchers to study the consequences of this interaction being blocked and thereby elucidate its regulatory role in translation initiation.
Solution Approach 2:
The small molecule inhibitors serve as simplified copies or mimics of the eIF1 protein's binding interface, allowing them to occupy the same binding site on eIF4G1 without having the full complexity of the actual eIF1 protein. This copying approach enables selective disruption of the protein-protein interaction while maintaining the spatial and chemical features necessary for binding, thereby revealing the functional significance of this interaction.
Data Source
AI summary
Methods of inhibiting eIF4G1 binding to eIF1, and inhibiting translation initiation are provided. Pharmaceutical compositions comprising inhibitors of eIF4G1-eIF1 binding and there use in treating disease are also provided.